메뉴 건너뛰기




Volumn 34, Issue 8, 2014, Pages 1016-1029

Opportunity cost of funding drugs for rare diseases: The cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria

Author keywords

Cost utility analysis; Markov models; Probabilistic sensitivity analysis

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

EID: 84909642930     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X14539731     Document Type: Article
Times cited : (58)

References (83)
  • 2
    • 84864856267 scopus 로고    scopus 로고
    • Ottawa: Bank of Canada; Available from: Accessed 19 March 2014
    • Bank of Canada inflation calculator. Ottawa: Bank of Canada; 2012. Available from: http://www.bankofcanada.ca/rates/related/inflation-calculator/. Accessed 19 March 2014.
    • (2012) Bank of Canada Inflation Calculator
  • 3
    • 22944483754 scopus 로고    scopus 로고
    • Incorporating economic evaluations into decisionmaking: The Ontario experience
    • Laupacis A. Incorporating economic evaluations into decisionmaking: the Ontario experience. Med Care. 2005;43(7, Suppl): 15-9.
    • (2005) Med Care , vol.43 , Issue.7 , pp. 15-19
    • Laupacis, A.1
  • 4
    • 31544452135 scopus 로고    scopus 로고
    • Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy
    • Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ. 2006;174(2):189-90.
    • (2006) CMAJ , vol.174 , Issue.2 , pp. 189-190
    • Clarke, J.T.1
  • 5
    • 74549137967 scopus 로고    scopus 로고
    • Toronto: Canadian Organization for Rare Disorders; Available from: Accessed 19 March 2014
    • Canadian Organization for Rare Disorders. Canada's Orphan Drug Policy: Learning from the Best. Toronto: Canadian Organization for Rare Disorders; 2005. Available from: http://www.raredisorders.ca/documents/CanadaOrphanDPFinal.pdf. Accessed 19 March 2014.
    • (2005) Canada's Orphan Drug Policy: Learning from the Best
  • 6
    • 27644486590 scopus 로고    scopus 로고
    • Orphan drugs and the NHS: Should we value rarity?
    • McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? Br Med J. 2005;331:1016-19.
    • (2005) Br Med J , vol.331 , pp. 1016-1019
    • McCabe, C.1    Claxton, K.2    Tsuchiya, A.3
  • 7
    • 78649652812 scopus 로고    scopus 로고
    • Policy alternatives for treatments for rare diseases
    • Panju AH, Bell CM. Policy alternatives for treatments for rare diseases. CMAJ. 2010;182(17):E787-92.
    • (2010) CMAJ , vol.182 , Issue.17 , pp. E787-E792
    • Panju, A.H.1    Bell, C.M.2
  • 8
    • 84866354190 scopus 로고    scopus 로고
    • An evaluation framework for funding drugs for rare disease
    • Winquist E, Bell CM, Clarke JTR, et al. An evaluation framework for funding drugs for rare disease. Value Health. 2012;15:982-6.
    • (2012) Value Health , vol.15 , pp. 982-986
    • Winquist, E.1    Bell, C.M.2    Clarke, J.T.R.3
  • 10
    • 77955318428 scopus 로고    scopus 로고
    • ?The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire
    • Hill A, Platts PJ, Smith A, et al. ?The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract 0067]. Haematologica. 2007;92(Suppl 2):25.
    • (2007) Haematologica , vol.92 , pp. 25
    • Hill, A.1    Platts, P.J.2    Smith, A.3
  • 11
    • 34047221441 scopus 로고    scopus 로고
    • Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
    • Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181-92.
    • (2007) Br J Haematol , vol.137 , Issue.3 , pp. 181-192
    • Hill, A.1    Richards, S.J.2    Hillmen, P.3
  • 12
    • 16044365965 scopus 로고    scopus 로고
    • Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors
    • French Society of Haematology
    • Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573-7.
    • (1996) Lancet , vol.348 , Issue.9027 , pp. 573-577
    • Socié, G.1    Mary, J.Y.2    De Gramont, A.3
  • 13
    • 35948962168 scopus 로고    scopus 로고
    • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    • Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123-8.
    • (2007) Blood , vol.110 , pp. 4123-4128
    • Hillmen, P.1    Muus, P.2    Dührsen, U.3
  • 14
    • 33748904355 scopus 로고    scopus 로고
    • The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    • Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-43.
    • (2006) N Engl J Med , vol.355 , Issue.12 , pp. 1233-1243
    • Hillmen, P.1    Young, N.S.2    Schubert, J.3
  • 15
    • 77955486794 scopus 로고    scopus 로고
    • Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
    • Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010; 85(8):553-9.
    • (2010) Am J Hematol , vol.85 , Issue.8 , pp. 553-559
    • Hillmen, P.1    Elebute, M.2    Kelly, R.3
  • 16
    • 79958849218 scopus 로고    scopus 로고
    • Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival
    • Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-92.
    • (2011) Blood , vol.117 , Issue.25 , pp. 6786-6792
    • Kelly, R.J.1    Hill, A.2    Arnold, L.M.3
  • 18
    • 0031886073 scopus 로고    scopus 로고
    • An introduction to Markov modelling for economic evaluation
    • Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409.
    • (1998) Pharmacoeconomics , vol.13 , Issue.4 , pp. 397-409
    • Briggs, A.1    Sculpher, M.2
  • 19
    • 0242494954 scopus 로고    scopus 로고
    • Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
    • Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102(10):3587-91.
    • (2003) Blood , vol.102 , Issue.10 , pp. 3587-3591
    • Hall, C.1    Richards, S.2    Hillmen, P.3
  • 20
    • 34247614032 scopus 로고    scopus 로고
    • Thrombosis in paroxysmal nocturnal hemoglobinuria: Sites, risks, outcome. An overview
    • Ziakas P, Poulou L, Rokas K, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5:642-5.
    • (2007) J Thromb Haemost , vol.5 , pp. 642-645
    • Ziakas, P.1    Poulou, L.2    Rokas, K.3    Bartzoudis, D.4    Voulgarelis, M.5
  • 21
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
    • (2009) Lancet Oncol , vol.10 , Issue.3 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 23
    • 34548384965 scopus 로고    scopus 로고
    • Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: A Canadian perspective
    • Coyle D, Rodby R, Soroka S, et al. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clin Ther. 2007;29:1508-23.
    • (2007) Clin Ther , vol.29 , pp. 1508-1523
    • Coyle, D.1    Rodby, R.2    Soroka, S.3
  • 24
    • 77956712811 scopus 로고    scopus 로고
    • Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusiondependent myelodysplastic syndrome patients
    • Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusiondependent myelodysplastic syndrome patients. J Med Econ. 2010;13(3):559-70.
    • (2010) J Med Econ , vol.13 , Issue.3 , pp. 559-570
    • Tolley, K.1    Oliver, N.2    Miranda, E.3    Migliaccio-Walle, K.4    Bozkaya, D.5    Li, Q.6
  • 25
    • 34247271478 scopus 로고    scopus 로고
    • Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusiondependent thalassaemia patients: US healthcare system perspective
    • Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusiondependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25:329-42.
    • (2007) Pharmacoeconomics , vol.25 , pp. 329-342
    • Delea, T.E.1    Sofrygin, O.2    Thomas, S.K.3    Baladi, J.F.4    Phatak, P.D.5    Coates, T.D.6
  • 27
    • 7944231114 scopus 로고    scopus 로고
    • The incidence and mortality for meningococcal disease associated with area deprivation: An ecological study of hospital episode statistics
    • Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child. 2004;89(11):1064-8.
    • (2004) Arch Dis Child , vol.89 , Issue.11 , pp. 1064-1068
    • Heyderman, R.S.1    Ben-Shlomo, Y.2    Brennan, C.A.3    Somerset, M.4
  • 29
    • 0028296769 scopus 로고
    • Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
    • Levine M, Hirsh J, Gent M. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343(8902):886-9.
    • (1994) Lancet , vol.343 , Issue.8902 , pp. 886-889
    • Levine, M.1    Hirsh, J.2    Gent, M.3
  • 30
    • 0037431013 scopus 로고    scopus 로고
    • Long-term, lowintensity warfarin therapy for the prevention of recurrent venous thromboembolism
    • Ridker PM, Goldhaber SZ, Danielson E. Long-term, lowintensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425-34.
    • (2003) N Engl J Med , vol.348 , Issue.15 , pp. 1425-1434
    • Ridker, P.M.1    Goldhaber, S.Z.2    Danielson, E.3
  • 32
    • 85044709641 scopus 로고    scopus 로고
    • Hormonal therapies for early breast cancer: Systematic review and economic evaluation
    • Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):iii-iv, ix-xi, 1-134.
    • (2007) Health Technol Assess , vol.11 , Issue.26
    • Hind, D.1    Ward, S.2    De Nigris, E.3    Simpson, E.4    Carroll, C.5    Wyld, L.6
  • 33
    • 32844464374 scopus 로고    scopus 로고
    • Health-related quality of life and estimates of utility in chronic kidney disease
    • Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801-8.
    • (2005) Kidney Int , vol.68 , pp. 2801-2808
    • Gorodetskaya, I.1    Zenios, S.2    McCulloch, C.E.3
  • 34
    • 0032925807 scopus 로고    scopus 로고
    • Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A cost-effectiveness analysis
    • Gould MK, Dembitzer AD, Sanders GD, Garner AM. Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med. 1999;130:789-99.
    • (1999) Ann Intern Med , vol.130 , pp. 789-799
    • Gould, M.K.1    Dembitzer, A.D.2    Sanders, G.D.3    Garner, A.M.4
  • 35
    • 82955169580 scopus 로고    scopus 로고
    • The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer
    • Younis T, Rayson D, Skedgel C. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol. 2011;18(6):e288-96.
    • (2011) Curr Oncol , vol.18 , Issue.6 , pp. e288-e296
    • Younis, T.1    Rayson, D.2    Skedgel, C.3
  • 37
    • 4844222413 scopus 로고    scopus 로고
    • The societal unit cost of allogenic red cells and red cell transfusion in Canada
    • Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red cells and red cell transfusion in Canada. Transfusion. 2004;44:1479-86.
    • (2004) Transfusion , vol.44 , pp. 1479-1486
    • Amin, M.1    Fergusson, D.2    Wilson, K.3
  • 38
    • 33745662843 scopus 로고    scopus 로고
    • Costeffectiveness of self-managed versus physician-managed oral anticoagulation therapy
    • Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Costeffectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006;174(13):1847-52.
    • (2006) CMAJ , vol.174 , Issue.13 , pp. 1847-1852
    • Regier, D.A.1    Sunderji, R.2    Lynd, L.D.3    Gin, K.4    Marra, C.A.5
  • 39
    • 79955774273 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
    • Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908-19.
    • (2011) Thromb Haemost , vol.105 , pp. 908-919
    • Sorensen, S.V.1    Kansal, A.R.2    Connolly, S.3
  • 40
    • 82755195008 scopus 로고    scopus 로고
    • Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: A prospective evaluation
    • Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost. 2011;9:2397-405.
    • (2011) J Thromb Haemost , vol.9 , pp. 2397-2405
    • Guanella, R.1    Ducruet, T.2    Johri, M.3
  • 41
    • 78549238147 scopus 로고    scopus 로고
    • Cost of transfusiondependent myelodysplastic syndrome (MDS) from a German payer's perspective
    • Kühne F, Mittendorf T, Germing U. Cost of transfusiondependent myelodysplastic syndrome (MDS) from a German payer's perspective. Ann Hematol. 2010;89:1239-47.
    • (2010) Ann Hematol , vol.89 , pp. 1239-1247
    • Kühne, F.1    Mittendorf, T.2    Germing, U.3
  • 43
    • 78349232816 scopus 로고    scopus 로고
    • Population based screening for chronic kidney disease: Cost effectiveness study
    • Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ. 2010;341:c5869.
    • (2010) BMJ , vol.341 , pp. c5869
    • Manns, B.1    Hemmelgarn, B.2    Tonelli, M.3
  • 45
    • 84879409410 scopus 로고    scopus 로고
    • Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation
    • Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498-506.
    • (2013) Value Health , vol.16 , Issue.4 , pp. 498-506
    • Coyle, D.1    Coyle, K.2    Cameron, C.3
  • 46
    • 84909625921 scopus 로고    scopus 로고
    • Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by provinces and territories
    • Public Health Agency of Canada. Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by provinces and territories. Can Communicable Dis Rep (CCDR). 2010;36:S2.
    • (2010) Can Communicable Dis Rep (CCDR) , vol.36 , pp. S2
    • Public Health Agency of Canada1
  • 47
    • 84909599134 scopus 로고    scopus 로고
    • Victoria: British Columbia Ministry of Health; Available from: Accessed 19 March 2014
    • British Columbia Ministry of Health. Pharmacare Formulary. Victoria: British Columbia Ministry of Health; 2012. Available from: http://www.health.gov.bc.ca/pharmacare/benefitslookup/. Accessed 19 March 2014.
    • (2012) Pharmacare Formulary
  • 48
    • 33846118263 scopus 로고    scopus 로고
    • Rates and probabilities in economic modelling: Transformation, translation and appropriate application
    • Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25:3-6.
    • (2007) Pharmacoeconomics , vol.25 , pp. 3-6
    • Fleurence, R.L.1    Hollenbeak, C.S.2
  • 49
  • 50
    • 0034086702 scopus 로고    scopus 로고
    • Handling uncertainty in cost-effectiveness models
    • Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
    • (2000) Pharmacoeconomics , vol.17 , pp. 479-500
    • Briggs, A.H.1
  • 51
    • 0026575912 scopus 로고
    • How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations
    • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
    • (1992) CMAJ , vol.146 , pp. 473-481
    • Laupacis, A.1    Feeny, D.2    Detsky, A.S.3    Tugwell, P.X.4
  • 52
    • 84909646437 scopus 로고    scopus 로고
    • Toronto: Ontario Nurses Association; Available from: Accessed 19 March 2014
    • Ontario Nurses Association. Unions and the Ontario Nurses' Association 2012. Toronto: Ontario Nurses Association; 2012. Available from: http://www.ona.org/faqs.html. Accessed 19 March 2014.
    • (2012) Unions and the Ontario Nurses' Association 2012
  • 53
    • 84909643222 scopus 로고    scopus 로고
    • Toronto, Canada: Ontario Ministry of Health and Long Term Care; Available from: Accessed 19 March 2014
    • Ontario Ministry of Health and Long Term Care. Ambulance Services Billing 2012. Toronto, Canada: Ontario Ministry of Health and Long Term Care; 2012. Available from: http://www.health.gov.on.ca/en/public/publications/ohip/amb.aspx. Accessed 19 March 2014.
    • (2012) Ambulance Services Billing 2012
  • 54
    • 84909630326 scopus 로고    scopus 로고
    • Available from: Accessed 19 March 2014
    • Manulife Canada. Long Term Care in Ontario 2010. Available from: https://repsourcepublic.manulife.com/wps/wcm/connect/repsourceFormsMktg/MarketingMaterials/Insurance/LivingCare/ins-livcare-ontarioltccostreport?presentationtemplate=repsourceDesign/showPDF. Accessed 19 March 2014.
    • Long Term Care in Ontario 2010
  • 55
    • 84927572690 scopus 로고    scopus 로고
    • November Available from: Accessed 19 March 2014
    • Mood Disorders Society of Canada. Quick Facts on Mental Illness and Addictions in Canada, 3rd Edition (November 2009). Available from: http://www.mooddisorderscanada.ca/page/quick-facts. Accessed 19 March 2014.
    • (2009) Quick Facts on Mental Illness and Addictions in Canada, 3rd Edition
  • 56
    • 84864198277 scopus 로고    scopus 로고
    • Orphan drugs for rare diseases: Is it time to revisit their special market access status?
    • Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72:1437-43.
    • (2012) Drugs , vol.72 , pp. 1437-1443
    • Simoens, S.1    Cassiman, D.2    Dooms, M.3    Picavet, E.4
  • 57
    • 0034822074 scopus 로고    scopus 로고
    • Managing public payment for high cost, high-benefit treatment: Enzyme replacement therapy for Gaucher's disease in Ontario
    • Clarke JTR, Amato D, Deber RB. Managing public payment for high cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ. 2001;165:595-6.
    • (2001) CMAJ , vol.165 , pp. 595-596
    • Clarke, J.T.R.1    Amato, D.2    Deber, R.B.3
  • 58
    • 27744461277 scopus 로고    scopus 로고
    • Drugs for exceptionally rare diseases: Do they deserve special status for funding?
    • Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829-36.
    • (2005) QJM , vol.98 , Issue.11 , pp. 829-836
    • Hughes, D.A.1    Tunnage, B.2    Yeo, S.T.3
  • 61
    • 84890848005 scopus 로고    scopus 로고
    • Can the NICE "end-of-life premium" be given a coherent ethical justification?
    • Cookson R. Can the NICE "end-of-life premium" be given a coherent ethical justification? J Health Polit Policy Law. 2013;38(6):1129-48.
    • (2013) J Health Polit Policy Law , vol.38 , Issue.6 , pp. 1129-1148
    • Cookson, R.1
  • 63
    • 84881344116 scopus 로고    scopus 로고
    • Prioritizing treatment of rare diseases: A survey of preferences of Norwegian doctors
    • Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56-62.
    • (2013) Soc Sci Med , vol.94 , pp. 56-62
    • Desser, A.S.1
  • 64
    • 84900754530 scopus 로고    scopus 로고
    • Health charities get 'covert' aid from drug firms
    • December 3
    • Templeton S-K. Health charities get 'covert' aid from drug firms. Sunday Times. December 3, 2006.
    • (2006) Sunday Times
    • Templeton, S.-K.1
  • 65
    • 84909599163 scopus 로고    scopus 로고
    • Building bridges to rare disease patients
    • September/October
    • White W. Building bridges to rare disease patients. Pharm Commerce. September/October 2012:14.
    • (2012) Pharm Commerce , pp. 14
    • White, W.1
  • 67
    • 84909579650 scopus 로고    scopus 로고
    • Toronto: Canadian Organization for Rare Disorders. Available from: Accessed 19 March 2014
    • Canadian Organization for Rare Disorders. Newsletter July 2012. Toronto: Canadian Organization for Rare Disorders. 2012. Available from: http://www.raredisorders.ca/documents/CORD-Summer2012Newsletter.v4.pdf. Accessed 19 March 2014.
    • (2012) Newsletter July 2012
  • 68
    • 84863369347 scopus 로고    scopus 로고
    • Rare diseases: Canada's "research orphans"
    • Gupta S. Rare diseases: Canada's "research orphans." Open Med. 2012;6(1):e24-7.
    • (2012) Open Med , vol.6 , Issue.1 , pp. e24-e27
    • Gupta, S.1
  • 69
    • 84909625920 scopus 로고    scopus 로고
    • Toronto: Canadian Organization for Rare Disorders; Available from: Accessed 19 March 2014
    • Canadian Organization for Rare Disorders. Corporate Leaders. Toronto: Canadian Organization for Rare Disorders; 2014. Available from: http://www.raredisorders.ca/CorporateCouncil.html. Accessed 19 March 2014.
    • (2014) Corporate Leaders
  • 72
    • 84862886261 scopus 로고    scopus 로고
    • The cost effectiveness of NHS physiotherapy support for occupational health (OH) services
    • Phillips CJ, Phillips R, Main CJ, et al. The cost effectiveness of NHS physiotherapy support for occupational health (OH) services. BMC Musculoskelet Disord. 2012;13:29.
    • (2012) BMC Musculoskelet Disord , vol.13 , pp. 29
    • Phillips, C.J.1    Phillips, R.2    Main, C.J.3
  • 73
    • 84897501016 scopus 로고    scopus 로고
    • Achieving allocative efficiency in healthcare: Nice in theory, not so NICE in practice?
    • Paulden M, McCabe C, Karnon J. Achieving allocative efficiency in healthcare: nice in theory, not so NICE in practice? Pharmacoeconomics. 2014;32(4):315-8.
    • (2014) Pharmacoeconomics , vol.32 , Issue.4 , pp. 315-318
    • Paulden, M.1    McCabe, C.2    Karnon, J.3
  • 74
    • 84897522245 scopus 로고    scopus 로고
    • Can the real opportunity cost stand up: Displaced services, the straw man outside the room
    • Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics. 2014;32(4):319-25.
    • (2014) Pharmacoeconomics , vol.32 , Issue.4 , pp. 319-325
    • Eckermann, S.1    Pekarsky, B.2
  • 75
    • 84861928513 scopus 로고    scopus 로고
    • Which orphans will find a home? The rule of rescue in resource allocation for rare diseases
    • Largent E, Pearson S. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42(1):27-34.
    • (2012) Hastings Cent Rep , vol.42 , Issue.1 , pp. 27-34
    • Largent, E.1    Pearson, S.2
  • 76
    • 55249116853 scopus 로고    scopus 로고
    • Public healthcare resource allocation and the rule of rescue
    • Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics. 2008;34:540-4.
    • (2008) J Med Ethics , vol.34 , pp. 540-544
    • Cookson, R.1    McCabe, C.2    Tsuchiya, A.3
  • 77
    • 84861951692 scopus 로고    scopus 로고
    • How should we model rare disease allocation decisions?
    • London AJ. How should we model rare disease allocation decisions? Hastings Cent Rep. 2012;42(1):3.
    • (2012) Hastings Cent Rep , vol.42 , Issue.1 , pp. 3
    • London, A.J.1
  • 78
    • 34250367132 scopus 로고    scopus 로고
    • OFT, VBP: QED?
    • Claxton K. OFT, VBP: QED? Health Econ. 2007;16:545-58.
    • (2007) Health Econ , vol.16 , pp. 545-558
    • Claxton, K.1
  • 79
    • 84863517632 scopus 로고    scopus 로고
    • Orphan drug development: An economically viable strategy for biopharma R&D
    • Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13-14):660-4.
    • (2012) Drug Discov Today , vol.17 , Issue.13-14 , pp. 660-664
    • Meekings, K.N.1    Williams, C.S.2    Arrowsmith, J.E.3
  • 80
    • 79958849417 scopus 로고    scopus 로고
    • Pricing and reimbursement of orphan drugs: The need for more transparency
    • Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
    • (2011) Orphanet J Rare Dis , vol.6 , pp. 42
    • Simoens, S.1
  • 81
    • 84888319689 scopus 로고    scopus 로고
    • Do ultra-orphan medicinal products warrant ultra-high prices? A review
    • Picavet E, Cassiman D, Simoens S. Do ultra-orphan medicinal products warrant ultra-high prices? A review. Orphan Drugs Res Rev. 2013;3:23-31.
    • (2013) Orphan Drugs Res Rev , vol.3 , pp. 23-31
    • Picavet, E.1    Cassiman, D.2    Simoens, S.3
  • 82
    • 84887541924 scopus 로고    scopus 로고
    • Funding innovation for treatment for rare diseases: Adopting a cost-based yardstick approach
    • Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Orphanet J Rare Dis. 2013;8:180.
    • (2013) Orphanet J Rare Dis , vol.8 , pp. 180
    • Fellows, G.K.1    Hollis, A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.